Migration of multiple sclerosis lymphocytes through brain endothelium

Archives of Neurology

Volumn 59, Issue 3, 2002, Pages 391-397

  Prat, Alexandre ^a,b   Biernacki, Katarzyna ^a   Lavoie, Jean Francois ^a   Poirier, Josee ^a   Duquette, Pierre ^b   Antel, Jack P ^a  

^a MCGILL UNIVERSITY   (Canada)

^b NOTRE DAME HOSPITAL   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

BETA1 INTEGRIN; CHEMOKINE; CHEMOKINE RECEPTOR; GAMMA INTERFERON INDUCIBLE PROTEIN 10; INTERLEUKIN 8; LYMPHOCYTE FUNCTION ASSOCIATED ANTIGEN 1; MATRIX METALLOPROTEINASE; MONOCLONAL ANTIBODY; MONOCYTE CHEMOTACTIC PROTEIN 1; RANTES; RIBONUCLEASE; TISSUE INHIBITOR OF METALLOPROTEINASE 1;

ADULT; ARTICLE; BLOOD BRAIN BARRIER; BRAIN; CELL MIGRATION; CLINICAL ARTICLE; CONTROLLED STUDY; ENDOTHELIUM; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; HUMAN CELL; MALE; MULTIPLE SCLEROSIS; PRIORITY JOURNAL; T LYMPHOCYTE;

EID: 0036186664     PISSN: 00039942     EISSN: None     Source Type: Journal    
DOI: 10.1001/archneur.59.3.391     Document Type: Article

References (40)

1. Lymphocyte migration and multiple sclerosis: Relation with disease course and therapy
2. Heterogeneity in T lymphocytes functions in primary progressive multiple sclerosis: Relation to MRI lesion volume
3. Migratory behavior of lymphocytes isolated from multiple sclerosis patients: Effects of interferon beta-1b therapy
4. Interferon beta-1b decreases the migration of T lymphocytes in vitro: Effects on matrix metalloproteinase-9
5. Characterization of transendothelial chemotaxis of T lymphocytes
6. Astrocyte-derived monocyte-chemoattractant protein-1 directs the transmigration of leukocytes across a model of the human blood-brain barrier
7. Adhesion of memory lymphocytes to vascular cell adhesion molecule-1-transduced human vascular endothelial cells under simulated physiological flow conditions in vitro
8. La expression by vascular endothelium is inducible by activated T cells and by human gamma interferon
9. Monocyte chemoattractant protein 1 acts as a T-lymphocyte chemoattractant
10. Ultrastructural localization of factor VIII-related antigen in cultured human brain microvessel endothelial cells
11. In vitro adhesion and migration of T lymphocytes across monolayers of human brain microvessel endothelial cells: Regulation by ICAM-1, VCAM-1, E-selectin and PECAM-1
12. Expression of vascular cell adhesion molecule-1 (VCAM-1) by human brain microvessel endothelial cells in primary culture
13. Brain microvascular endothelial cells and leukocytes derived from patients with multiple sclerosis exhibit increased adhesion capacity
14. Interferon-beta inhibits activated leukocyte migration through human brain microvascular endothelial cell monolayer
15. The induction of ICAM-1 in human cerebromicrovascular endothelial cells (HCEC) by ischemia-like conditions promotes enhanced neutrophil/HCEC adhesion
16. Differential regulation of adhesion molecule expression by human cerebrovacular and umbilical vein endothelial cells
17. Interaction between myelin basic protein-sensitized T lymphocytes and murine cerebral vascular endothelial cells
18. B7 expression and antigen presentation by human brain endothelial cells: Requirement for proinflammatory cytokines
19. Increased expression of bioactive chemokines in human cerebromicrovascular endothelial cells and astrocytes subjected to simulated ischemia in vitro
20. Molecular cloning and functional expression of a novel CC chemokine receptor cDNA from a human basophilic cell line
21. Monocyte chemoattractant protein-3 is a functional ligand for CC chemokine receptors 1 and 2B
22. Transendothelial chemotaxis of human alpha/beta and gamma/delta T lymphocytes to chemokines
23. C-C chemokines, but not the C-X-C chemokines interleukin-8 and interferon-gamma inducible protein-10, stimulate transendothelial chemotaxis of T lymphocytes
24. Expression of monocyte chemoattractant protein-1 and other beta-chemokines by resident glia and inflammatory cells in multiple sclerosis lesions
25. MCP-1, MCP-2 and MCP-3 expression in multiple sclerosis lesions: An immunohistochemical and in situ hybridization study
26. Expression of MCP-1 by reactive astrocytes in demyelinating multiple sclerosis lesions
27. Acute and relapsing experimental autoimmune encephalomyelitis are regulated by differential expression of the CC chemokines macrophage inflammatory protein-1alpha and monocyte chemotactic protein-1
28. Localization of monocyte chemoattractant peptide-1 expression in the central nervous system in experimental autoimmune encephalomyelitis and trauma in the rat
29. MIP-1alpha and MCP-1 differentially regulate acute and relapsing autoimmune encephalomyelitis as well as Th1/Th2 lymphocyte differentiation
30. Sequence polymorphisms in the chemokines Scya1 (TCA-3), Scya2 (monocyte chemoattractant protein (MCP)-1), and Scya12 (MCP-5) are candidates for eae7, a locus controlling susceptibility to monophasic remitting/nonrelapsing experimental allergic encephalomyelitis
31. Defining the clinical course of multiple sclerosis: Results of an international survey
32. Interferon-gamma secretion by peripheral blood T-cell subsets in multiple sclerosis: Correlation with disease phase and interferon-beta therapy
33. CCR5(+) and CXCR3(+) T cells are increased in multiple sclerosis and their ligands MIP-1alpha and IP-10 are expressed in demyelinating brain lesions
34. Activated suppressor cell function in severely disabled patients with multiple sclerosis
35. Expression pattern of activation and adhesion molecules on peripheral blood CD4+ T-lymphocytes in relapsing-remitting multiple sclerosis patients: A serial analysis
36. VLA-4 expression on peripheral blood lymphocytes is downregulated after treatment of multiple sclerosis with interferon beta
37. MCP-1 and IL-8 trigger firm adhesion of monocytes to vascular endothelium under flow conditions
38. Astrocyte expression of mRNA encoding cytokines IP-10 and JE/MCP-1 in experimental autoimmune encephalomyelitis
39. CC chemokine receptor 2 is critical for induction of experimental autoimmune encephalomyelitis
40. Effective treatment of models of multiple sclerosis by matrix metalloproteinase inhibitors